Zilretta Kit
Product Images NDC 65250-003

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Zilretta (NDC 65250-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pacira Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zilretta 01)

Chemical structure diagram of triamcinolone acetonide, the active ingredient in Zilretta extended-release injectable suspension. The structure displays steroid rings and functional groups typical of corticosteroids.*

FDA Label Image

Figure 1 (Zilretta 02)

Line graph showing LS mean change from baseline in Average Daily Pain (ADP) on a 0-10 scale over 12 weeks post treatment. It compares Zilretta (triamcinolone acetonide extended-release injectable suspension), placebo, and an active control (immediate-release triamcinolone acetonide). The graph displays treatment groups with different markers, illustrating changes from baseline pain scores across the study period.*

FDA Label Image

Figure 1 (Zilretta 03)

An instructional illustration showing components supplied and not supplied in the Zilretta kit. The 'Supplied' section includes a vial, a smaller vial or ampule, and a device component. The 'Not Supplied' section shows a syringe, three individual packets, and three larger packets, indicating these items are not included in the kit.*

FDA Label Image

Figure 2 (Zilretta 04)

An instructional illustration showing a hand tapping on a small, oval-shaped item placed on a flat surface, with the word 'Tap' indicating the action. The image is likely part of usage instructions for Zilretta, triamcinolone acetonide extended-release injectable suspension kit by Pacira Pharmaceuticals, Inc.*

FDA Label Image

Figure 3 (Zilretta 05)

An instructional illustration showing two vials. The left vial labeled 'INCORRECT' has a cloudy suspension with a cross over it, indicating it should not be used. The right vial labeled 'CORRECT' shows a clear suspension, indicating the proper appearance of the product before use.*

FDA Label Image

Figure 4 (Zilretta 06)

Illustration showing a pair of gloved hands handling a vial and a syringe, demonstrating preparation steps typical for an injectable suspension like Zilretta (triamcinolone acetonide extended-release), intended for intra-articular use.*

FDA Label Image

Figure 5 (Zilretta 07)

An instructional illustration showing two gloved hands opening or handling a component, likely part of a medical kit such as the Zilretta triamcinolone acetonide extended-release injectable suspension kit for intra-articular use.*

FDA Label Image

Figure 6 (Zilretta 08)

An instructional illustration showing a vial labeled Zilretta powder vial, with an arrow indicating placement of an adapter on the vial. A close-up inset shows the Zilretta powder vial with the adapter securely in place, demonstrating preparation for use.*

FDA Label Image

Figure 7 (Zilretta 09)

An illustration showing gloved hands handling a medical component labeled as a plastic holder. One hand is holding the plastic holder with a vial or syringe inserted, while the other hand is pulling a cap or protective cover upwards, indicated by a large arrow pointing up.*

FDA Label Image

Figure 8 (Zilretta 10)

An instructional illustration showing a gloved hand attaching a vial adapter to a ZILRETTA powder vial while holding a syringe, demonstrating preparation of the triamcinolone acetonide extended-release injectable suspension kit for intra-articular use.*

FDA Label Image

Figure 9 (Zilretta 11)

An instructional line drawing showing gloved hands preparing Zilretta, a powder vial of triamcinolone acetonide extended-release injectable suspension, for intra-articular injection. One hand holds the vial while the other inserts a syringe into the vial.*

FDA Label Image

Figure 10 (Zilretta 12)

An instructional illustration showing a gloved hand tapping a vial gently with a syringe inserted. The image demonstrates a step in preparing an injectable suspension, likely emphasizing mixing or settling of the medication prior to administration.*

FDA Label Image

Figure 11 (Zilretta 13)

An instructional illustration showing the correct and incorrect methods of withdrawing medication from a vial, indicating that the syringe should be inserted vertically without tilting. The left side labeled 'INCORRECT' shows the syringe tilted, while the right side labeled 'CORRECT' shows the syringe inserted straight down into the vial.*

FDA Label Image

Figure 12 (Zilretta 14)

Instructional illustration showing correct and incorrect techniques for handling a syringe in the Zilretta kit. The left side, marked incorrect, depicts improper syringe manipulation, while the right side, marked correct, shows proper syringe handling with one hand steadying the syringe and the other hand adjusting the plunger.*

FDA Label Image

Figure 13 (Zilretta 15)

An instructional illustration showing two steps of handling a syringe by a gloved hand. The first panel depicts a hand gripping the syringe with an arrow indicating a twisting motion. The second panel shows the same hand holding the syringe upright with an arrow pointing in a forward direction, indicating the next step in syringe preparation or use.*

FDA Label Image

Figure 14 (Zilretta 16)

An instructional illustration for Zilretta kit showing the correct and incorrect syringe appearance. The correct syringe image shows a uniform suspension, while the incorrect syringe image shows the suspension separated and not fully mixed. Both illustrations depict the syringe used for intra-articular injection.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Zilretta 32 mg per vial, a triamcinolone acetonide extended-release injectable suspension kit for intra-articular injection by Pacira Pharmaceuticals, Inc. The label notes it is a single-dose kit including microsphere powder, diluent, and a vial adapter, with storage instructions and a barcode displayed.*

FDA Label Image

Principal Display Panel (32 mg Vial Label)

Label for Zilretta 32 mg per vial (triamcinolone acetonide extended-release injectable suspension) by Pacira Pharmaceuticals. It is a sterile single-dose vial for intra-articular injection, must be reconstituted with supplied diluent, and includes storage instructions to refrigerate at 2-8°C or store at 20-25°C for up to 6 weeks. Label includes NDC 65250-001-01 and barcode.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Packaging label for Zilretta diluent, a 5 mL sterile single-use vial for use with Zilretta. Contains sodium chloride, sodium carboxymethylcellulose, and polysorbate-80 in aqueous solution. Labeler is Pacira Pharmaceuticals, Inc. Instructions note not to administer directly and storage at 2-25°C (36-77°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.